a b s t r a c t c-Aminobutyric acid (GABA) is considered to be the most important inhibitory neurotransmitter in the central nervous system, including the retina. It has been shown that nitric oxide (NO) can influence the physiology of all retinal neuronal types, by mechanisms including modulation of GABA release. However, until now, there have been no data concerning the effects on endogenous GABA release of NO produced by cells in the intact retina. In the present study, we have investigated how NO production induced by drugs influences the release of endogenous GABA in cells of the intact retina of mature chicken. Retinas were exposed to different drugs that affect NO production, and GABA remaining in the tissue was detected by immunohistochemical procedures. A specific nNOS inhibitor (7-NI) reduced the number of GABA + amacrine cells and cells in the ganglion cell layer (GCL) by 33% and 41%, respectively. A GABA transporter inhibitor blocked this effect. L-arginine (100 lM), the precursor of NO, induced increases of 62% and 34% in the number of GABA + amacrine cells and GCL cells, respectively. A sodium (Na + )-free solution, 7-NI and a PKG inhibitor prevented the effect of L-arginine (100 lM). However, a higher concentration of L-arginine (1 mM) induced a 35% reduction in the number of GABA + cells by a Na + -dependent mechanism that was restricted to the GCL population. NMDA, which stimulates NO production, increased GABA release as indicated by 53% and 38% reductions in the number of GABA + amacrine cells and GCL cells, respectively. This effect was blocked by 7-NI only in GCL cells. We conclude that basal NO production and moderate NO production (possibly induced by L-arginine; 100 lM) inhibit basal GABA release from amacrine cells and GCL cells. However, NMDA or L-arginine (1 mM) induce a NO-dependent increase in GABA release in GCL cells, possibly by stimulating higher NO production.
Introduction
c-Aminobutyric acid (GABA) and glutamate are considered, respectively, to be the most important inhibitory and excitatory neurotransmitters in the central nervous system (CNS), including in the retina of different animal species (Massey & Redburn, 1987; Mosinger, Yazulla, & Studholme, 1986; Thoreson & Witkovsky, 1999; Yazulla, Studholme, Vitorica, & De Blas, 1989) . In the retina, the vertical pathway is formed by glutamatergic cells that transmit information from photoreceptors to bipolar cells and then to ganglion cells, which are responsible for sending the information to superior visual centers (Barnstable, 1993; Massey & Maguire, 1995; Thoreson & Witkovsky, 1999) . Horizontal and amacrine GABAergic cells modulate the activity of the vertical pathway, forming the lateral pathway (Barnstable, 1993; Sun & Crossland, 2000; Tachibana & Kaneko, 1988; Yazulla, 1986) . The interaction between the glutamatergic vertical pathway and the GABAergic lateral pathway is very important for the processing of visual information in the retina, mainly for simultaneous contrast.
According to Sun and Crossland (2000) , almost 100% of amacrine cells express GABA and/or glycine, and more than 60% are GABAergic. Most GABAergic amacrine cells receive glutamatergic inputs from bipolar cells (Marc & Liu, 2000) . A number of investigators used different methods to analyze GABA content of specific cell populations in several species. From these studies, it was demonstrated that L-glutamate and its analogues promote GABA release via a calcium-independent and sodium (Na + )-dependent process, in fish, amphibian, avian, and some mammalian retinas (Andrade da Costa, De Mello, & Hokoç, 2000; Ayoub & Lam, 1984; Morán & Pasantes-Morales, 1983; O'Malley and Masland, 1989; Tapia & Arias, 1982; Yazulla, 1983; Yazulla & Kleinschmidt, 1982 , 1983 . Nevertheless, a small amount of GABA release via a calcium-dependent, probably vesicular exocytotic release seemed to take place (Campochiaro, Ferkany, & Coyle 1985 1983). Basal and stimulated-GABA release also take place through calcium-independent mechanisms in other areas of the CNS (Bernath & Zigmond, 1988; Schoffelmeer et al., 2000) .
During the development of the 14-day-old embryonic (E14) chick into the post-hatching (PE) animal, a major part of retinal amacrine cells release GABA in response to the activation of NMDA receptors, which form one class of ionotropic glutamate receptors (iGluRs) (Calaza, De Mello, & Gardino, 2001; Calaza, Fialho De Mello, Garcia De Mello, & Gardino, 2003) . The NMDA receptor is associated with nitric oxide synthase (NOS) through PSD-95, a 95 KDa postsynaptic density protein (Brenman et al., 1996) . NOS catalyzes the formation of nitric oxide (NO) and L-citruline from L-arginine (Stuehr, 1999) , and the activation of NMDA receptors represents the main mechanism for NOS activation and NO production in the CNS. In embryonic retinal cell cultures, activation of NMDA receptors stimulates NO production, which induces [ 3 H]-GABA release (Ientile et al., 1997) . NO is a gaseous messenger molecule with many different functions in the CNS, including modulation of neurotransmitter release (Hirsch et al., 1993; Li, Chen, & Pan, 2002; Ohkuma, Narihara, Katsura, Hasegawa, & Kuriyama, 1995; Prast & Philippu, 2001; Segieth, Getting, Biggs, & Whitton, 1995; Trabace & Kendrick, 2000) . It has been reported that NO stimulates GABA release in different CNS regions (Lonart, Wang, & Johnson, 1992; Ohkuma et al., 1995; Segovia, Porras, & Mora, 1994; Ozaki et al., 2000; Li et al., 2002; Saransaari & Oja, 2006; Segovia & Mora, 1998) , including the retina (Ientile et al., 1996; Ientile et al., 1997; Yu & Eldred, 2005) . NOS colocalization with GABA has been reported in the retina of several species (Andrade da Costa et al., 2000; Haverkamp, Kolb, & Cuenca, 2000; Oh, Kim, Lee, Chun, & Chung, 1998; Weiler & Kewitz, 1993) . Oh and co-workers (1998) have shown that all NOS-immunoreactive neurons express GABA in the rat and rabbit retina.
It has been shown that NO modulates GABA release in a biphasic way in different CNS regions (Getting, Segieth, Ahmad, Biggs, & Whitton, 1996; Jayakumar et al., 1999; Paul & Ekambaram, 2005) . In the mouse hippocampus, GABA release is stimulated by NMDAmediated NO production or by a large dose of the NO donor SNAP (1 or 2 mM). However, a lower concentration (500 lM) of the same NO donor reduces GABA release (Getting et al., 1996) , suggesting that different NO concentrations might generate opposite effects.
Previous data suggest that NO may have an important role in retinal visual processing. Accordingly, NO has been shown to influence the physiology of all neuronal types in the retina. For instance, NO decreases the strength of coupling of mGluR6 to downstream elements in its signal transduction cascade pathway (Snellman & Nawy, 2004) , blocks gap junctions between horizontal cells (Pottek, Schultz, & Weiler, 1997) and also junctions between AII amacrine cells and cone bipolars cells (Mills & Massey, 1995) . Moreover, lack of nNOS reduces the sensitivity of ganglion cells to light (Wang, van der List, Nemargut, Coombs, & Chalupa, 2007) .
These many actions of NO in the retina could possibly be due to modulation of neurotransmitter release. However, until now, there have been no data about the effects of cell-derived NO on endogenous GABA levels. Moreover, such modulation was not studied in the intact chicken retina, which preserves cell connections and tissue environment.
In the present study, we have investigated the modulation of endogenous GABA release by NO in the mature chick intact retina.
Materials and methods

Reagents and drugs
L-arginine, L-glutamate, glycine, polyclonal rabbit primary antiserum against GABA, gelatin, diaminobenzidine, NMDA and EDTA were obtained from Sigma (St. Louis, MO, USA). Biotinylated goat anti-rabbit IgG and avidin-biotin complex were obtained from Vector. KT5823 was purchased from Calbiochem (San Diego, CA, USA), 7-NI from Biomol (Plymouth Meeting, PA, USA) and . Other reagents were bought from common commercial sources.
Animals
Fertilized White Leghorn eggs were obtained from a local hatchery. The procedures for the use of animals were in accordance with the ''NIH guide for the Care and Use of Laboratory Animals" and approved (# IBCCF001) by the commission of animal care (CEUA-CCS) of the Centro de Ciências da Saúde of Federal University of Rio de Janeiro.
Tissue stimulation
For all experiments the animals were sacrificed, at the same period of the day, by decapitation and then the eyes were enucleated. In each experiment we used only one animal and each retina was divided into two pieces, designated randomly as ''control" or as ''experimental". In addition, we used at least three different animals for each treatment. Retinas were incubated in Locke's solution (157 mM NaCl, 5.6 mM KCl, 2.3 mM CaCl 2 , 1 mM MgCl 2 , 3.6 mM Na 2 HCO 3 , 5.0 mM HEPES and 5.6 mM glucose) or Hanks' solution (128 mM NaCl, 4 mM KCl, 1 mM MgCl 2 , 3 mM CaCl 2 , 4 mM glucose, 20 mM HEPES) balanced with 95% O 2 /5% de CO 2 , and pH adjusted to 7.2-7.4 with HCl 1 N and NaOH 1 N solutions (or LiOH 1 N in experiments in which Na + was suppressed). During the stimulation period, retinas were kept in a bath solution at 37°C with frequent shaking.
Retinal pieces were incubated in 500 lL of Locke's or Hanks' solution (control) or in the same solutions containing one of the following drugs that affect NO production: the specific nNOS inhibitor, 7-nitroindazole (7-NI 100 lM) for 25 min; a substrate for NO production, L-arginine (100 lM, 500 lM or 1 mM) for 25 minincubation with L-arginine was also performed without Na + , whereupon the ion was replaced by lithium; and NMDA receptor agonist, NMDA (100 lM), for 30 min. Experiments with NMDA were performed in the absence of MgCl 2 , and in the presence of the divalent cation chelator, EDTA (2 mM), and with glycine (2 mM).
Some retinal pieces were pre-incubated with one of the following compounds: NOS inhibitor (7-NI 100 lM) for 10 min; GABA transporter inhibitor (NO-711 100 lM) for 20 min; and cyclic GMP-dependent protein kinase (PKG) inhibitor (KT5823, 1 lM)
for 10 min. The drugs used during the pre-incubation period were maintained during the following 25-min period of incubation with L-arginine.
Tissue fixation
Immediately after tissue stimulation, retinal segments were fixed by immersion in 4% paraformaldehyde (diluted in 0.16 M phosphate buffer (PB), pH 7.2) for 2 h. The segments were rinsed with PB and then cryoprotected in sucrose (15% and 30%). After 24 h, retinas were mounted in OCT embedding medium (Sakura Finetek, Torrance, CA), frozen, and cryosectioned. Sections perpendicular to the vitreal surface (10-12 lm) were collected from the whole retina onto gelatinized slides. Sections of control tissue and from different treatment conditions were collected on the same glass slide to avoid differences during immunohistochemical procedure.
Immunohistochemical procedure
Slides with sections of control and experimental retinas were first washed in sodium phosphate-buffered saline (PBS). Then, the tissue was pre-incubated with 2% bovine serum albumin (BSA) for 1 h, and incubated overnight with polyclonal rabbit primary antiserum against GABA (1:4000; Sigma). After several rinses in PBS, the sections were incubated with biotinylated goat antirabbit IgG (1:200; Vector) for 2 h. Further washes in PBS were made and the sections incubated with a complex of biotin-avidin (1:50; Vectastain Elite, Vector) for 1 h 30 min. Finally, sections were rinsed in PBS twice for 10 min and incubated with 0.05% 3,3-diaminobenzidine and 0.01% hydrogen peroxide solution for 10 min. After three rinses, the slides were mounted with glycerol (40% in PB). Immunohistochemical control sections were incubated with PBS or rabbit normal serum in the absence of primary antibody, and no immunoreactivity was detected.
Cell quantification
Quantification of the GABA-immunoreactive cell number was possible because, in all experiments, control and experimental groups were processed for immunohistochemistry in the same slide and treated with all reagents at the same time and under the same conditions. Therefore, there were no differences in the histological or immunohistochemical procedures between control and experimental retinas. All sections were examined and studied under light microscopy (Axioskop microscope, Zeiss) and photographed with Nikon 80i.
Cells were considered GABA-positive (GABA+) when their staining was clearly distinguished from the background, i.e., generally the staining in the upper part of the INL (where Müller and bipolar cell bodies are localized), which does not show GABA-immunoreactivity in the chick retina.
We counted GABA + cells localized at the ganglion cell layer (GCL) and at the first three cell body tiers of the inner portion of the INL, the region in which amacrine cells are found. We analyzed these cell types because they are the chicken retinal GABAergic cell subpopulations that produce NOS (Fischer & Stell, 1999) . The total numbers of amacrine cells and of cells in the GCL were always obtained from six fields/section of at least three sections for each retinal treatment in each experiment. In addition, in each experiment, at least 190 cells in the GCL and 570 cells along three rows of cell bodies in the innermost part of the inner nuclear layer were counted in each control retina. Also, we used at least three different animals for each treatment. We adjusted the microscope focus in order to see cells more clearly, and we found about two or three different focuses in which we could identify and count cells accurately. The data were analyzed statistically using one-way ANOVA and the Bonferroni Post-test. Data are shown as mean ± standard error of the mean (mean ± SEM).
Results
In agreement with previous results in the chick retina (Calaza et al., 2001) , no differences were observed between GABA-immunoreactivity patterns in tissue fixed immediately after dissection and in retinal pieces incubated in Locke's solution (not illustrated). GABA-containing cells were mainly distributed in the three innermost layers of somata in the inner nuclear (INL) and ganglion cell layers (GCL). In addition, GABA-immunoreactive horizontal cells were also observed, always constituting a single row of cells. The IPL also showed an intense GABA-immunolabelling (Figs. 1A-5A ).
Treatment with a nNOS inhibitor (7-NI) induced a 33% decrease in GABA + amacrine cell number (Fig. 1B and D) and a 41% decrease in GABA + cell number in the GCL (Fig. 1B and E ) in comparison to the control (Fig. 1A) . The effect of 7-NI was probably to be due to an increase in GABA efflux, since it was blocked by NO-711, a selective neuronal GABA transporter (GAT1) inhibitor (Fig. 1C-E) . Thus, it seems that when 7-NI inhibited basal NO production, it increased GABA efflux and, consequently, reduced the GABA + cell number.
NO synthesis is induced by providing L-arginine to cells, since L-arginine is the precursor for NO production by NOS (Kakuda, Finley, Maruyama, & MacLeod, 1998; Kurz & Harrison, 1997; Nicholson, Manner, Kleeman, & MacLeod 2001) . Paul and Jayakumar (1999) reported a significant increase of NO levels in rat brains treated with a high, but not a low, concentration of L-arginine, suggesting that different concentrations of L-arginine would produce distinct levels of NO. Therefore, we decided to test the effects of different L-arginine concentrations on GABA release. When the retina was exposed to 100 lM L-arginine for 25 min, we verified 62%
and 34% increases in GABA + amacrine cell number ( Fig. 2B and D) and GABA + cell number in the GCL ( Fig. 2B and E) , respectively, in comparison to control ( Fig. 2A) . The effect of L-arginine was specifically due to NO production, since it was blocked by 7-NI ( Fig. 2F and G). The fact that L-arginine induces an increase in GABA + cell number ( Fig. 2B ) is in agreement with the reduction in GABA + cell number induced by 7-NI treatment in the cells of the GCL and INL (Fig. 1B) . These data suggested that both basal and moderate levels of NO production (the latter induced by 100 lM L-arginine) inhibit GABA release. On the other hand, higher concentrations of L-arginine, 500 lM (data not shown) or 1 mM, did not affect the number of GABA + amacrine cells ( Fig. 2C and D) . In the GCL, 500 lM L-arginine also did not alter the number of GABA + cells (data not shown), but 1 mM L-arginine induced a 35% reduction in GABA + -cell number ( Fig. 2C and E) compared to the control ( Fig. 2A) . Therefore, these data support the idea that GABA release is induced by higher NO levels in GCL cells, and it is reasonable to suggest that 1 mM L-arginine could produce such levels of NO.
The data also suggest a biphasic modulation of GABA release by NO in cells of the GCL, and that such modulation would depend on the NO concentration achieved.
In the retina, the main mechanism of GABA release is the reversal of the GABA transporter (Calaza, Gardino, & De Mello, 2006; Calaza et al., 2001; Carvalho, Ferreira, Carvalho, & Duarte, 1995; Do Nascimento & De Mello, 1985; Duarte, Ferreira, Santos, Oliveira, & Carvalho, 1993; Ferreira, Duarte, Santos, & Carvalho, 1994; Morán & Pasantes-Morales, 1983; Schwartz, 1987; Tapia & Arias, 1982; Yazulla, 1983; Yazulla & Kleinschmidt, 1983) . In order to investigate if the effects of 100 lM and 1 mM L-arginine on GABA efflux involve the modulation of the Na + -dependent GABA transporter, retinas were exposed to a Na + -free Ringer for 25 min. The absence of Na + blocked the effects of the previously mentioned concentrations of L-arginine ( Fig. 3C and D) , supporting the idea that NO modulates GABA efflux that is induced by reversal of the transporter.
Since NO can activate intracellular pathways that stimulate cyclic GMP-dependent protein kinase (PKG) (Linden, Dawson, & Dawson, 1995) , we decided to study the involvement of the NO/ PKG pathway in the modulation of the GABA transporter by NO production induced by L-arginine (100 lM). Retinas were treated with the PKG inhibitor KT5823 (1 lM) and incubated with or without L-arginine (100 lM). KT5823 blocked the expected L-arginine (100 lM)-induced increase in the number of GABA + amacrine cells ( Fig. 4C and D) and the number of GABA + cells in the GCL (Fig. 4C and E) . However, KT5823 had no effect when incubated alone ( Fig. 4D and E) , suggesting that the inhibitory effect in the GABA transporter by moderate NO levels, probably induced by 100 lM L-arginine, depends on the NO-PKG pathway, whereas the effect of basal NO does not.
NO biosynthesis by nNOS in the brain is preferentially activated by calcium influx through NMDA receptors, which form a postsynaptic complex with nNOS assembled by PSD-95 (Brenman et al., 1996) . In the present study, retinas treated with NMDA (100 lM)
for 30 min showed a reduction in GABA + amacrine cell number (53%, Fig. 5B and D) and GABA + cell number in the GCL (38%, Fig. 5B and E) in comparison to control retinas (Fig. 5A) . Treatment with the NOS inhibitor 7-NI (100 lm) during NMDA incubation blocked the NMDA effect on GCL cell somas ( Fig. 5C and E) , but not the effect on amacrine cell somas ( Fig. 5C and D) . This result indicates that GABA efflux induced by NMDA is only mediated by NO in the GCL, but not in amacrine cells. Also, this is in agreement with the data showing that 1 mM L-arginine induces GABA efflux only in the GCL, and supports the hypothesis that the GABA efflux induced by NO in GCL cells depends on high levels of NO, probably produced by 1 mM L-arginine or NMDA receptor activation.
Discussion
In this work, we found that NO can differently modulate GABA release in distinct cell populations of the mature retina. In amacrine cells, basal or moderate NO levels inhibit tonic GABA release, but high NO levels do not have any effect on endogenous GABA release. In GCL cells, as in amacrine cells, the same modulation by basal or moderate NO levels occurs; however, high NO levels increase GABA release.
The NO effect on GABA release seems to be due to its capacity to modulate Na + -dependent GABA transporter reversal. Several studies have shown that GABA release in the retina of several species occurs mainly via a calcium-independent and Na 1982, 1983) . The possibility that NO could be modulating GABA uptake was ruled out, because if the 1 mM L-arginine and 7-NI effects were due to inhibition of GABA uptake, then the blockade of GABA transporter should not interfere with the results. As highlighted above, this was not the case, since the incubation in Na + -free Ringer or NO-711 blocked the decrease in the number of GABA-positive cells induced by, respectively, 1 mM L-arginine or 7-NI treatment. Taken together, our results suggest that the NO effect was mostly due to modulation of GABA efflux, through reversal of the GABA transporter, rather than GABA uptake.
NO mechanisms of GABA metabolism modulation
Besides modulating GABA release, NO can also modulate GABA synthesis in the retina. In the chick retina, a NO donor (SNAP) reduced by more than 60% the activity of glutamic acid decarboxylase (GAD), the enzyme responsible for GABA synthesis (Almeida et al., 2002) . NO can also regulate GABA degradation in some regions of the CNS Paul & Ekambaram, 2005; ), but such modulation has not been verified in the retina yet. In our work, NO-induced increase or decrease in GABA + cells was totally blocked by an inhibitor of the GABA transporter or by incubation in Na + -free solution. These results in the post-hatched chick retina suggest that the NO effect was mostly due to modulation of GABA release, through reversal of the GABA transporter, rather than a reduction in its degradation or synthesis.
Biphasic effect of NO
NO has been reported to be both proconvulsant (Bagetta Values represent mean ± SEM. ÃÃ p < 0.01 with respect to control. N = 3 experiments were performed in triplicate. 100% of control corresponds to 960 ± 85 (mean ± SEM) amacrine cells (D) and 261 ± 38.7 cells in the GCL (E) counted in control retina. INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. The same abbreviations are used for all following figures. CTR, control; 7-NI, specific nNOS inhibitor; NO-711, specific inhibitor of the neuronal GABA transporter. Davis, & Subramanian, 1994; Przegalinski, Baran, & Siwanowicz, 1994) . Segieth and collaborators (1995) reported that in rat hippocampus, the NO donor SNAP (500 lM) decreases tonic in vivo glutamate release, but higher concentrations of SNAP (1-2 mM) increases glutamate release. The same group also showed a similar biphasic effect of the NO donor SNAP on GABA release (Getting et al., 1996) and suggested that the NO biphasic effect on glutamate and GABA release would explain those data that show both an excitatory and an inhibitory action of the molecule. In our results, a NO biphasic effect on GABA + cell number was also verified.
Our data show that basal NO production inhibits tonic GABA release in GCL cells and topic amacrine cells, since the decrease in NO production caused by 7-NI, a selective inhibitor of nNOS, reduced the GABA + cell number. This effect seems to involve GABA release, since it was blocked by NO-711, a selective inhibitor of the neuronal GABA transporter. Additionally, retinal stimulation with 100 lM L-arginine, the substrate for NO production, induces an increase in the GABA + cell number. This effect was apparently due to an L-arginine-triggered production of NO, once it was blocked by 7-NI. The 100 lM L-arginine effect was also blocked by a Na + -free Ringer, indicating that the effect of augmenting NO production by 100 lM L-arginine involves inhibition of Na + -dependent, transporter-mediated GABA release. A negative regulation of GABA signaling by NO in the retina has already been shown by Wexler, Stanton, and Nawy (1998) , whose study found that NO depresses GABA A receptor function.
In contrast, the treatment with a high concentration of L-arginine (1 mM) decreased GABA + cell number in the GCL, but not in the INL-localized amacrine cells. A Na + -free Ringer blocked this effect, indicating that the effect of augmenting NO production by 1 mM L-arginine involves transporter-mediated GABA release (Calaza et al., 2001; Tapia & Arias, 1982; Yazulla & Kleinschmidt, 1982) . We also propose that, as in the hippocampus (Getting et al., 1996) , NO exerts a biphasic modulation of GABA release in GCL cells. GABA release was inhibited by basal and moderate NO levels, but was induced by higher NO levels. On the other hand, GABAergic topic amacrine cells in the INL are only negatively modulated by basal or moderate NO production. Consequently, in the retina, it could be suggested that the overall amount of neuronal excitability may depend on the concentration of NO modulating GABA release.
NO production by NMDA receptor activation
Exposure of chick embryo retinal cells to low (10 lM) or high (100 lM) concentrations of NMDA increases NOS activity, by, respectively, 0.5-or 6-fold (Ientile et al., 1997) . Therefore, our data showing a reduction of NMDA (100 lM)-evoked GABA release from GCL cells by NO is probably due to a high NO production after NMDA receptor stimulation. In addition, NMDA-induced GABA release was blocked by 7-NI in cells of the GCL, but not in topic amacrine cells. This result supports the idea that the modulation of GABA release by higher levels of NO occurs only in GCL cells. The decrease of GABA-immunoreactivity in retinas exposed to NMDA is not due to an eventual GABA leakage from damaged cells, but probably due to transporter-mediated neurotransmitter release, as we have previously shown (Calaza et al., 2001) . tion depends on NO production. The difference between these reports and ours could be explained by the different methodologies used. For instance, NO released by a NO donor may not be equivalent to NO production by the cell, especially with respect to the time and concentration of the production of this molecule. Unpublished data from our group showed that a 500 lM NO donor (SNAP) treatment for 60 min is necessary to achieve the same effect as treatment with 100 lM L-arginine for 25 min. This indicates how different treatments can generate variable availability of NO. Thus, since NO produced by donors or from substrates (e.g. L-arginine) may have distinct kinetics of production or availability, caution should be taken when comparing their effects. Also, GABA taken up by exogenous sources is not necessarily in the same pool as GABA synthesized by the cell (Campochiaro, Ferkany, & Coyle, 1984) . Yu and Eldred (2005) have also raised the possibility that distinct NO effects on specific neurons can be explained by three other factors: the availability of NO target molecules in a particular neuron, the synaptic connections of the neuron and the physiological oxidation state of the neuronal microenvironment. Here, we investigated for the first time the modulation of endogenous GABA release by nitric oxide produced by the intact chick retina (ex vivo preparation). Indeed, NO effects on GABA release depend on the level of NO production and also on the cellular type. The mechanism of inhibition of tonic GABA release induced by the basal NO level is different from that stimulated by moderate levels of NO. In agreement with this idea, an inhibitor of PKG (KT5823) blocked the 100 lM L-arginine-mediated inhibition of GABA release but not the effect of basal NO. This suggests that basal NO inhibition of tonic GABA release is independent of PKG, whereas moderate NO production, stimulated by 100 lM L-arginine, inhibits tonic GABA release through the activation of PKG. Supporting the idea that NO can act through different pathways depending on specific cell populations, it has been previously shown that a NO donor stimulates GVG release from horizontal cells primarily through a cGMP-mediated pathway, whereas in amacrine cells, peroxynitrite plays a larger role (Yu & Eldred, 2005) . In agreement with these findings, we found that the increase in GABA release induced by high NO production following treatment with 1 mM L-arginine occurs only in cells in the GCL, however the mechanism remains unclear.
Although activation of the calcium-dependent protein kinase (PKC) could inhibit the GABA transporter 1 (GAT1) (Beckman, Bernstein, & Quick, 1998; Cristóvão-Ferreira, Vaz, Ribeiro, & Sebastião, 2009; Gomeza, Casado, Gimenez, & Aragon, 1991) , the role of PKC and the relationship to PKG activation in our experiments remain to be clarified.
NO effects on visual responses
It has already been described that an increase or decrease of NO production can have powerful effects on visual responses. Whole cell current-clamp recordings from ganglion cells of the ferret retina treated with 5 mM L-arginine showed a reduction in ON-responses, and also a complete blockage of APB-sensitive rod OFF-responses (Wang, Liets, & Chalupa, 2003) . Similar results were found in the mouse retina (Wang, 2006) . On the other hand, sensitivity to light was also decreased in nNOS knockout retina. The threshold of light intensities required to evoke optimal responses was significantly higher in the nNOS knockouts than in the wildtype retina (Wang et al., 2007) . The mechanisms underlying modulation of ganglion cells sensitivity by NO are not known, but seem to be related to the regulation of retinal function by NO. As we have reported here, basal NO production is necessary to maintain the normal, tonic GABA release, and the same is required to promote normal visual responses (Wang, 2006; Wang et al., 2003 Wang et al., , 2007 . Here, we have demonstrated that different NO levels regulate GABA release in a biphasic way, however it remains unclear exactly how GABA release induced by different concentrations of NO interferes with visual responses.
